Glucocorticoid Induced Whole Body Catabolisme
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The main purpose of the trial is to advance our knowledge on the possible mechanism underlying the catabolic effects of long-term treatment with glucocorticoid.
Full description
Long-term treatment with glucocorticoid induces a general state of catabolism and increases insulin resistance. The underlying mechanisms are insufficiently characterized, however glucocorticoid induced changes of Growth Hormone (GH) and the Insulin-like growth factor I (IGF-I) appear to be of outmost importance.
We wish to investigate the mechanism behind glucocorticoid induced catabolism and insulin resistance.
More specific we wish to investigate:
Whether glucocorticoid induces IGF-I inhibiting substances in serum or interstitial fluid that block the ability of IGF-I to phosphorylate its receptor in vitro Whether glucocorticoid inhibits intracellular IGF-I and insulin signaling in vitro and in vivo The mechanisms by which growth hormone counteracts the CG-mediated inhibition of IGF-I action
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- signed and dated informed consent
- healthy subjects
- sex: male
- age 20-30 years
- BMI 19-26 kg/m2
- normal HbA1c
Exclusion criteria
- suspected og known allergy to the trial drug or similar medications.
- known current illness including diabetes mellitus, ischemic heart disease or cardiac arrhythmia.
- Daily drug intake (excluding Over-the-Counter medicines).
- Known or previous mental illness
- Current participation or previous participation in experiments using ionizing radiation for a year prior to inclusion in this study.
- Participation in a larger X-ray examinations in trial period.
Trial design
Primary purpose
Allocation
Interventional model
Masking
19 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal